http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008127252-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 |
| filingDate | 2006-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008127252-A |
| titleOfInvention | FGFR3 INHIBITOR EFFECTS ON GENE TRANSCRIPTION |
| abstract | 1. A method for identifying a patient for treatment, comprising:! administering to the patient an amount of an FGFR3 inhibitor and! testing a sample obtained from a patient after administration of an inhibitor to measure gene expression of at least one biomarker selected from Table I,! moreover, the detection of changes in the level of expression compared with the initial level of at least one biomarker indicates the patient's candidacy for treatment. ! 2. A method for identifying a patient for treatment, comprising:! testing a sample obtained from a patient to measure gene expression of at least one biomarker selected from Table I,! moreover, the detection of the presence of gene expression of at least one biomarker indicates the patient's candidacy for treatment. ! 3. A method for monitoring the response of a patient in need of this to the treatment of cell proliferative disorder, which consists in:! administering to the patient an amount of an FGFR3 inhibitor,! testing a sample obtained from a patient after administration of an inhibitor to measure gene expression of at least one biomarker selected from Table I,! moreover, the detection of changes in the expression level of at least one biomarker compared with the initial level is an indicator of a patient's favorable response to treatment. ! 4. A method for monitoring the patient's response to treatment with an FGFR3 inhibitor of cell proliferative disease, comprising:! testing a sample obtained from a patient to measure gene expression of at least one biomarker selected from Table I,! moreover, the detection of changes in the expression level of at least one biomarker |
| priorityDate | 2005-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.